What the Yale Study on CBG Actually Found

Cannabigerol (CBG) has moved from a footnote in cannabinoid science to the subject of serious laboratory research. One of the studies driving that shift came out of Yale School of Medicine in 2025. Here is what it actually looked at, and just as importantly what it did not.

What the study examined

The 2025 paper, published in PNAS (Proceedings of the National Academy of Sciences) from the lab of Mohammad-Reza Ghovanloo at Yale, investigated how several cannabinoids including CBG and CBD interact with voltage-gated sodium channels. Sodium channels are proteins that help nerve cells send electrical signals, which is why they are a frequent focus of nerve-signaling research.

The headline finding

Among the cannabinoids the group tested, CBG showed the strongest effect on inhibiting these sodium channels, a stronger effect than CBD in the same comparison. Because most cannabinoid research to date has focused on CBD in isolation, a head-to-head comparison like this is genuinely useful.

How to read it responsibly

• It is laboratory work, not a human clinical trial. The study describes activity at the cellular level. The mechanism is documented; the clinical implications are still being studied.
• It compared cannabinoids directly, which is rare and adds real information about how CBG behaves differently from CBD at the molecular level.
• It gives a plausible mechanism for why CBG might behave differently than CBD in nerve-related contexts, something that, until recently, was mostly an anecdotal observation.

Where it fits

A companion body of work from Penn State (2022 and 2023) has explored complementary aspects of cannabinoid activity. Between the two research groups, we now have a clearer molecular picture of why CBG is chemically distinct from CBD. The original Yale paper is open-access on the PNAS website if you want to read the primary source.

At Steadfast Health, we make SteadCalm Micellar CBG Serum, a water-soluble CBG topical with Vitamin E for daily nerve wellness. We follow this research closely and describe it as what it is: research on CBG as a compound, not a claim about our product.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.